1. 1. Liu CY, Chen KF, Chen PJ (2015) Treatment of Liver Cancer. Cold Spring Harb Perspect Med, 5(9): a021535. [DOI:10.1101/cshperspect.a021535]

2. Jeong S, Zheng B, Wang H, et al. (2018) Nervous system and primary liver cancer. Biochim Biophys Acta Rev Cancer, 1869(2): 286-92. [DOI:10.1016/j.bbcan.2018.04.002]

3. Sung H, Ferlay J, Siegel RL, et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a Cancer Journal for Clinicians, 71(3): 209-49. [DOI:10.3322/caac.21660]

4. Feng M, Pan Y, Kong R, et al. (2020) Therapy of primary liver cancer. Innovation (Cambridge (Mass)), 1(2): 100032. [DOI:10.1016/j.xinn.2020.100032]

5. Orcutt ST, Anaya DA (2018) Liver resection and surgical strategies for management of primary liver cancer. Cancer Control, 25(1): 1073274817744621. [DOI:10.1177/1073274817744621]

6. Xu ZJ, Wei MJ, Zhang XM, et al. (2022) Effects of microwave ablation on serum Golgi protein 73 in patients with primary liver cancer. World J Gastroenterol, 28(29): 3971-80. [DOI:10.3748/wjg.v28.i29.3971]

7. Liu F, Hou B, Li Z, et al. (2023) Microwave ablation of multifocal primary liver cancer guided by real-time 3.0T MRI. Int J Hyperthermia, 40(1): 2228519. [DOI:10.1080/02656736.2023.2228519]

8. Zhang W, Zhu W, Yang J, et al. (2021) Augmented reality navigation for stereoscopic laparoscopic anatomical hepatectomy of primary liver cancer: preliminary experience. Front Oncol, 11: 663236. [DOI:10.3389/fonc.2021.663236]

9. Liang P, Yu J, Lu MD, et al. (2013) Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy. World J Gastroenterol, 19(33): 5430-8. [DOI:10.3748/wjg.v19.i33.5430]

10. Yoshida H, Taniai N, Yoshioka M, et al. (2019) Current status of laparoscopic hepatectomy. J Nippon Med Sch, 86(4): 201-6. [DOI:10.1272/jnms.JNMS.2019_86-411]

11. Ren H, An C, Liang P, et al. (2019) Ultrasound-guided percutaneous microwave ablation assisted by athree-dimensional visualization treatment platform combined with transcatheter arterial chemoembolization for a single large hepatocellular carcinoma 5 cm or larger: a preliminary clinical application. Int J Hyperthermia, 36(1): 44-54. [DOI:10.1080/02656736.2018.1530459]

12. Suwa K, Seki T, Aoi K, et al. (2021) Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis. Abdominal radiology (New York), 46(8): 3790-7. [DOI:10.1007/s00261-021-03008-9]

13. Wang Y, Cheng Z, Yu J, et al. (2020) US-guided percutanous microwave ablation for early-stage hepatocellular carcinoma in elderly patients is as effective as in younger patients: A 10-year experience. Journal of Cancer Research and Therapeutics, 16(2): 292-300. [DOI:10.4103/jcrt.JCRT_1021_19]

14. Peng Y, Cui D, Li W, et al. (2021) Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma originating in the caudate lobe: A pilot clinical study. Journal of Cancer Research and Therapeutics, 17(3): 764-70. [DOI:10.4103/jcrt.JCRT_1851_20]

15. Minami Y, Nishida N, Kudo M (2014) Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI. World Journal of Gastroenterology, 20(15): 4160-6. [DOI:10.3748/wjg.v20.i15.4160]

16. Nishino M (2018) Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond. Am Soc Clin Oncol Educ Book, 38:1019-29. [DOI:10.1200/EDBK_201441]

17. Shi JF, Cao M, Wang Y, et al. (2021) Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer, 148(5): 1051-65. [DOI:10.1002/ijc.33313]

18. Li X, Ramadori P, Pfister D, et al. (2021) The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer, 21(9): 541-57. [DOI:10.1038/s41568-021-00383-9]

19. Salazar J, Le A (2021). The Heterogeneity of Liver Cancer Metabolism. Adv Exp Med Biol, 1311: 127-36. [DOI:10.1007/978-3-030-65768-0_9]

20. Zhou H and Song T (2021). Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends, 15(3): 155-60. [DOI:10.5582/bst.2021.01091]

21. Izzo F, Granata V, Grassi R, et al. (2019) Radiofrequency ablation and microwave ablation in liver tumors: an update. Oncologist, 24(10): e990-e1005. [DOI:10.1634/theoncologist.2018-0337]

22. Xu Z, Yang Z, Pan J, et al. (2018) Individualized laparoscopic B-ultrasound-guided microwave ablation for multifocal primary liver cancer. Wideochir Inne Tech Maloinwazyjne, 13(1): 9-16. [DOI:10.5114/wiitm.2018.72730]

23. Fang L, Meng X, Luo W, et al. (2019) Treatment of primary hepatic carcinoma through ultrasound-guided microwave ablation. Niger J Clin Pract, 22(10): 1408-11. [DOI:10.4103/njcp.njcp_368_18]

24. Ran B, Chang YL, Qi J, et al. (2021) The clinical effects of ultrasound-guided microwave ablation in the treatment of primary hepatic carcinoma: Protocol for a retrospective clinical observation. Medicine (Baltimore), 100(48): e28045. [DOI:10.1097/MD.0000000000028045]

25. Zhang D, Chen Z, Zhang L, et al. (2023) Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis. J Vis Exp, 3: (193). [DOI:10.3791/64895]

26. Tinguely P, Fusaglia M, Freedman J, et al. (2017). Laparoscopic image-based navigation for microwave ablation of liver tumors-A multi-center study. Surg Endosc, 31(10): 4315-24. [DOI:10.1007/s00464-017-5458-4]

27. Zhang DL, Chen S, Lin YC, et al. (2022) Ultrasound-guided thermal ablation versus laparoscopic surgery for focal nodular hyperplasia of the liver: A retrospective controlled study. Frontiers in Oncology, 12: 932889. [DOI:10.3389/fonc.2022.932889]

28. Senitko M, Oberg CL, Abraham GE, et al. (2022) Microwave ablation for malignant central airway obstruction: a pilot study. Respiration, 101(7): 666-74. [DOI:10.1159/000522544]

29. Thomas MN, Dieplinger G, Datta RR, et al. (2021). Navigated laparoscopic microwave ablation of tumour mimics in pig livers: a randomized ex-vivo experimental trial. Surg Endosc, 35(12): 6763-9. [DOI:10.1007/s00464-020-08180-5]

30. Xia Y, Li J, Liu G, et al. (2020). Long-term Effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMA Oncol, 6(2): 255-63. [DOI:10.1001/jamaoncol.2019.4477]

31. Zhong H, Hu R, Jiang YS (2022) Evaluation of short- and medium-term efficacy and complications of ultrasound-guided ablation for small liver cancer. World Journal of Clinical Cases, 10(14): 4414-24. [DOI:10.12998/wjcc.v10.i14.4414]

32. Ma S, Ding M, Li J, et al. (2017). Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma: clinical outcomes and prognostic factors. Journal of Cancer Research and Clinical Oncology, 143(1): 131-42. [DOI:10.1007/s00432-016-2266-5]

33. Krasnick BA, Sindram D, Simo K, et al. (2019) Tumor ablation using 3-dimensional electromagnetic-guided ultrasound versus standard ultrasound in a porcine model. Surg Innov, 26(4): 420-6. [DOI:10.1177/1553350619825717]

34. Pan WD, Zheng RQ, Nan L, et al. (2010) Ultrasound-guided percutaneous microwave coagulation therapy with a "cooled-tip needle" for the treatment of hepatocellular carcinoma adjacent to the gallbladder. Dig Dis Sci, 55(9): 2664-9. [DOI:10.1007/s10620-009-1053-4]

35. Lech G, Słotwiński R, Słodkowski M, et al. (2016) Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol, 22(5): 1745-55. [DOI:10.3748/wjg.v22.i5.1745]

36. Zhao K, Zhou X, Xiao Y, et al. (2022) Research Progress in alpha-fetoprotein-induced immunosuppression of liver cancer. Mini Rev Med Chem, 22(17): 2237-43. [DOI:10.2174/1389557522666220218124816]

37. Liu H, Xu Y, Xiang J, et al. (2017). Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer. Clin Cancer Res, 23(2): 478-88. [DOI:10.1158/1078-0432.CCR-16-1203]

38. Munson PV, Adamik J, Butterfield LH (2022) Immunomodulatory impact of α-fetoprotein. Trends Immunol, 43(6): 438-48. [DOI:10.1016/j.it.2022.04.001]

39. Sun LY, Cen WJ, Tang WT, et al. (2022) Alpha-fetoprotein ratio predicts alpha-fetoprotein positive hepatocellular cancer patient prognosis after hepatectomy. Dis Markers, 2022: 7640560. [DOI:10.1155/2022/7640560]

40. Bacac M, Fauti T, Sam J, et al. (2016) A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of Solid Tumors. Clin Cancer Res, 22(13): 3286-97. [DOI:10.1158/1078-0432.CCR-15-1696]

41. Bray AW, Duan R, Malalur P, et al. (2022) Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer. Prostate, 82(13): 1264-72. [DOI:10.1002/pros.24400]

42. Kong Y, Jing Y, Sun H, et al. (2022) The Diagnostic Value of Contrast-Enhanced Ultrasound and Enhanced CT Combined with Tumor Markers AFP and CA199 in Liver Cancer. J Healthc Eng, 2022: 5074571. [DOI:10.1155/2022/5074571]

43. Scarà S, Bottoni P, Scatena R (2015) CA 19-9: Biochemical and clinical aspects. Adv Exp Med Biol, 867: 247-60. [DOI:10.1007/978-94-017-7215-0_15]

44. Lin ZP, Huang DB, Zou XG, et al. (2023) Percutaneous microwave ablation and transcatheter arterial chemoembolization for serum tumor markers and prognostics of middle-late primary hepatic carcinoma. World J Gastrointest Surg, 15(12): 2783-91. [DOI:10.4240/wjgs.v15.i12.2783]

45. Chen YY, Yen HH (2011) Subcutaneous metastases after laparoscopic-assisted partial hepatectomy for hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech, 21(1): e41-3. [DOI:10.1097/SLE.0b013e3182078ac3]

46. Ruterbusch M, Pruner KB, Shehata L, et al. (2020) In vivo CD4(+) T cell differentiation and function: Revisiting the Th1/Th2 paradigm. Annu Rev Immunol, 38: 705-25. [DOI:10.1146/annurev-immunol-103019-085803]

47. Reina-Campos M, Scharping NE, Goldrath AW (2021) CD8(+) T cell metabolism in infection and cancer. Nat Rev Immunol, 21(11): 718-38. [DOI:10.1038/s41577-021-00537-8]

48. Overgaard NH, Jung JW, Steptoe RJ, et al. (2015) CD4+/CD8+ double-positive T cells: more than just a developmental stage? J Leukoc Biol, 97(1): 31-8. [DOI:10.1189/jlb.1RU0814-382]

49. Zhou W, Yu M, Mao X, et al. (2022) Landscape of the peripheral immune response induced by local microwave ablation in patients with breast cancer. Adv Sci (Weinh), 9(17): e2200033. [DOI:10.1002/advs.202200033]

50. An C, Hu ZL, Liang P, et al. (2018) Ultrasound-guided percutaneous microwave ablation vs. surgical resection for thoracoabdominal wall implants from hepatocellular carcinoma: intermediate-term results. International journal of hyperthermia, 34(7): 1067-76. [DOI:10.1080/02656736.2017.1402131]